Reassuring findings were presented at the American Society of Hematology Annual Meeting at the beginning of December 2014 regarding the use of the immunomodulatory drug Lenalidomide. Concerns for patients with myelodysplastic syndrome (MDS) being administered this potent anti-cancer drug were quelled, when a comprehensive study revealed that this lifesaving treatment did not lead to a transformation to AML in Lenalidomide patients. Results from this study were deemed to be landmark, as it was the largest retrospective cohort study to date examining the concern of AML (acute myeloid leukemia) transformation in MDS patients. Findings were disseminated by Dana E. Rollison, PhD of the H. Lee Moffitt Cancer Center, and included data from approximately 1,248 patients who received Lenalidomide at the Moffitt Cancer Center between 2004 and 2012.
The aforementioned study met the great need for additional information regarding the risk of AML transformation in MDS patients, particularly the people with both the del 5q and non-del 5q forms of this cancer. As a retrospective analysis, the information gleaned offered the opportunity for researchers to gather real world data in a controlled manner. The follow up period of roughly 30 months proved that the administration of Lenalidomide was associated with a sizably reduced risk of AML transformation in patients, 2.44 per 100 person-years and 5.5 per 100 person–years in the patient group that received Lenalidomide and the group that did not, respectively. Additionally, a protective effect from Lenalidomide was found in patients with a lower risk on The International Prognostic Scoring System (IPSS), which is the most commonly used tool in myelodysplastic syndrome to predict long-term outcomes. These findings are not only reassuring to patients with MDS, but also encouraging for practitioners treating this virulent cancer.
Lenalidomide affects the immune system by helping to slow tumor growth, as well as effectively treating cancer which results from progressive blood disease, or multiple myeloma. Patients with myelodysplastic syndrome, which is caused by an abnormal chromosome (deletion 5q MDS), receive effectual treatment from the use of Lenalidomide, as do patients with mantle cell lymphoma, a rare cancer affecting the lymph nodes. Common adverse effects include itching, diarrhea and exhaustion. Lenalidomide is currently available only via a certified pharmacy under a special program, which can be accessed from certain practitioners. LGM Pharma can assist clients as a supplier/distributor of the API Lenalidomide CAS# 191732-72-6, for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.